Welcome to our dedicated page for Contineum Therapeutics SEC filings (Ticker: CTNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Contineum Therapeutics, Inc. SEC filings document a clinical-stage biopharmaceutical company developing oral small-molecule therapies for neuroscience, inflammation and immunology indications. The filing record covers PIPE-791 and PIPE-307 clinical disclosures, including trial data, protocol updates and Regulation FD materials tied to the company’s development programs.
Contineum’s filings also address quarterly financial results, proxy governance, board and compensation matters, Nasdaq inducement equity plans, Class A common stock registered on Nasdaq, and financing activity through shelf registration statements, underwritten offerings and sales-agreement arrangements. These documents describe the company’s capital structure, governance framework, risk-related clinical disclosures and material-event reporting.
Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain reported an open-market sale of 4,170 shares of Class A Common Stock at a weighted average price of $13.1564 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on September 23, 2025.
After this transaction, he holds 139,372 shares directly and 10,110 shares indirectly through his spouse. His holdings include 3,268 shares purchased through Contineum’s Employee Stock Purchase Plan on May 15, 2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to proposed sales of Common stock tied to Restricted Stock Units. The filing lists 4170 (unit) entries and documents multiple 10b5-1 sales by Daniel Lorrain on 05/01/2026, 04/06/2026 and 03/02/2026 with dollar amounts shown alongside each entry.
RA Capital Management and affiliated reporting persons reported beneficial ownership of 1,296,012 shares of Contineum Therapeutics Class A Common Stock, representing 4.0% of the class as of March 31, 2026. The percentage is calculated using 32,673,536 shares outstanding as of February 27, 2026, per the issuer's Form 10-K. The disclosure states the Fund directly holds 1,296,012 shares and that voting and investment power over those shares has been delegated to RA Capital; the filing contains formal disclaimers of beneficial ownership by certain reporting persons for purposes of Section 13(d).
Contineum Therapeutics, Inc. filing reports that Balyasny Asset Management and affiliated entities may be deemed to beneficially own 2,417,723 shares of Class A common stock, representing approximately 7.40% of the class. The shares are held directly by Atlas Diversified Master Fund, Ltd. and the filing attributes voting and investment power to BAM and related reporting persons based on their managerial roles. The 7.40% calculation is based on 32,673,536 Shares outstanding as of February 27, 2026 per the issuer's 10-K.
Contineum Therapeutics reported Q1 2026 results showing a net loss of $14.5 million, slightly improved from $16.0 million a year earlier, as it continues investing in its neuroscience, inflammation and immunology pipeline.
Research and development expenses were $11.6 million, down from $13.7 million, mainly as trials for PIPE-307 and earlier PIPE-791 studies wound down, partly offset by spending on the new Phase 2 IPF trial for PIPE-791. General and administrative costs rose to $5.3 million, driven largely by higher stock-based compensation and headcount.
Cash, cash equivalents and marketable securities totaled $246.3 million as of March 31, 2026, and management believes this will fund operations for at least 12 months. The company amended its at-the-market program to allow up to $100.0 million of additional Class A share sales but did not use it in the quarter. Contineum highlighted positive Phase 1b chronic pain data for PIPE-791 and ongoing collaboration with J&J on PIPE-307, including J&J’s Phase 2 Moonlight-1 depression trial.
Contineum Therapeutics reported first-quarter 2026 results, highlighting clinical progress and a strengthened financial position. The company recently announced positive topline data from an exploratory Phase 1b trial of PIPE-791 for chronic osteoarthritis or low back pain, which met its safety and tolerability objective and showed numerically greater pain improvements versus placebo. It also began patient dosing in PROPEL-IPF, a 26-week global Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis, and Johnson & Johnson is running the Phase 2 Moonlight-1 trial of PIPE-307/JNJ-89495120 in major depressive disorder.
Cash, cash equivalents and marketable securities totaled $246.3 million as of March 31, 2026, and the company expects its cash runway to extend through mid-2029. Research and development expenses were $11.6 million, a 15 percent decrease from the first quarter of 2025, while general and administrative expenses were $5.3 million, a 20 percent increase. Net loss was $14.5 million for the quarter, compared with $16.0 million a year earlier, or $0.39 per share based on 37,339,026 weighted-average shares outstanding.
Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain reported open-market sales of company stock. On May 1, 2026, he sold a total of 4,170 shares of Class A Common Stock in two transactions at weighted average prices of $13.06 and $13.84 per share, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025.
After these sales, he holds 143,542 shares directly and 6,842 shares indirectly through his spouse. The prices reflect multiple trades within reported ranges between $12.69 and $13.86 per share.
CTNM affiliate reported planned sales of Common Stock via Form 144. The filing lists multiple 10b5-1 programmed sales by Daniel Lorrain on several dates in 2026, including trades of 4,170, 3,824, 4,300, and other share amounts with indicated proceeds per trade. The filing names Morgan Stanley Smith Barney LLC as the broker and shows the securities type as Restricted Stock Units dated 05/09/2017.
Contineum Therapeutics, Inc. is asking stockholders to vote at its fully virtual 2026 Annual Meeting on June 26, 2026 at 8:00 a.m. Pacific Time via webcast after advance registration at www.proxydocs.com/CTNM.
Stockholders will vote on electing three Class II directors—Evert Schimmelpennink, Lori M. Lyons‑Williams and Diego Miralles, M.D.—to serve until the 2029 annual meeting, and on ratifying Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. Only holders of the 32,723,877 shares of Class A common stock outstanding as of April 27, 2026 may vote, with one vote per share. The board recommends voting “FOR” all director nominees and “FOR” auditor ratification.